25B-NBOMe: Difference between revisions

Line 4:

'''25B-NBOMe''' (also known as '''Cimbi-36''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].

'''25B-NBOMe''' (also known as '''Cimbi-36''', '''NBOMe-2C-B''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].

The name 25B-NBOMe, which short-hand for 2C-B-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-B]]. It was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref>Ralf Heim (February 28, 2010). [http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts."] (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMID 24397362. https://doi.org/10.1021/cn400216u</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" />

@@ Line 4: / Line 4: @@
 {{SubstanceBox/25B-NBOMe}}
-'''25B-NBOMe''' (also known as '''Cimbi-36''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].
+'''25B-NBOMe''' (also known as '''Cimbi-36''', '''NBOMe-2C-B''' and '''2C-B-NBOMe''') is novel synthetic [[Psychoactive class::psychedelic]] substance of the [[chemical class::phenethylamine]] chemical class. It produces an array of visually-dominant and stimulating [[psychedelic]] effects when [[Routes of administration|administered]].
 The name 25B-NBOMe, which short-hand for 2C-B-NBOMe, is a derivative of the phenethylamine psychedelic [[2C-B]]. It was discovered in 2004 by Ralf Heim at the Free University of Berlin.<ref>Ralf Heim (February 28, 2010). [http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221 "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts."] (in German). diss.fu-berlin.de. Retrieved 2013-05-10.</ref> It acts as a potent partial agonist for the 5-HT<sub>2A</sub> receptor.<ref name="25BSAR">Hansen, M.; Phonekeo, K.; Paine, J. S.; Leth-Petersen, S.; Begtrup, M.; Bräuner-Osborne, H.; Kristensen, J. L. (2014). "Synthesis and Structure-Activity Relationships of N-Benzyl Phenethylamines as 5-HT2A/2C Agonists". ACS Chemical Neuroscience. 5 (3): 243–9. PMID 24397362. https://doi.org/10.1021/cn400216u</ref> It has been used in clinical trials with an evaluation dose for safety consideration to humans of only 1 microgram. Such a dose was determined to be only 1/300th the dose expected to be hallucinogenic to humans and that recreational use would greatly exceed doses determined to be safe to humans.<ref name="25BSAR" />